NYSE$DHR

Danaher Corp · Q3 2025 earnings

Q3 2025 earnings · · Before market open · Investor relations

Briefing

Danaher reported Q3 2025 sales of $6.05B with net earnings of $908M and diluted EPS of $1.27.

Sales were $6.05 billion for the period ended September 26, 2025, with net earnings of $908 million and diluted EPS of $1.27. Life sciences and diagnostics businesses contributed to operating profit while the company continued portfolio and productivity initiatives.

  • Q3 sales $6.05B; net earnings $908M; diluted EPS $1.27.
  • Bioprocessing and diagnostics end markets influence segment mix.
  • Operating profit reflects cost actions and innovation spending.
  • Cash flow supports acquisitions and shareholder returns.

Headline financials

Total Revenue

$6.05B

Previous: $5.8B+4.4%
EPS (adj)

$1.27

Previous: $1.12+13.4%
Core Sales Growth

3.0%

No prior period
Biotech Core Sales Growth

6.5%

No prior period
Life Sciences Core Sales

-1.0%

No prior period
Diagnostics Core Sales

3.5%

No prior period
Capital Expenditures

-$785M

Previous: -$876M+10.4%
Free Cash Flow

$123M

Previous: -$58M+312.1%
Net Income

$908M

Previous: $818M+11.0%
Operating Income

$1.15B

Previous: $958M+20.5%
Gross Profit

$3.52B

Previous: $3.4B+3.6%
Total Assets

$79.9B

Previous: $80.6B-0.9%
R&D Expense

$378M

Previous: $383M-1.3%

Revenue & EPS history

Danaher · Revenue · Quarterly

$6.05B

Q3 2025+4.4%vs Q3 2024
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Forward guidance

The filing discusses Danaher's outlook, capital allocation, and key risks for upcoming quarters, including operating priorities and balance-sheet flexibility where disclosed.

Tailwinds

  • Danaher cites demand and execution supporting the near-term outlook.
  • Liquidity and balance-sheet capacity support operations and shareholder returns.

Headwinds

  • Macro, input costs, and FX may pressure margins quarter to quarter.
  • Segment mix and one-time items can affect comparability versus prior periods.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

+0.0%

Avg return

Earnings day

+0.0%

Avg return

5 days after

+0.3%

Avg return

30 days after

42%

31 / 73 earnings

Positive

+7.0%

Q4 2020

Best reaction

-9.7%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.5%-9.0%-12.2%
Q4 2025-5.4%-7.5%-11.6%
Q3 2025+6.1%+7.0%+6.6%
Q2 2025-0.4%+5.2%-4.0%
Q1 2025+3.8%+6.6%+1.4%
Q4 2024-9.7%-11.1%-17.9%
Q3 2024-5.9%-9.8%-13.6%
Q2 2024+5.9%+9.2%+6.8%
Q1 2024+6.1%+4.4%+10.7%
Q4 2023+2.6%+5.7%+9.7%
Q3 2023-5.6%-7.9%+8.5%
Q2 2023+2.7%+0.8%-1.7%
Q1 2023-8.6%-6.9%-9.4%
Q4 2022-5.1%-4.0%-8.8%
Q3 2022-5.2%-2.3%+1.1%
Q2 2022+7.0%+8.0%+14.2%
Q1 2022-5.6%-10.5%-10.2%
Q4 2021+5.4%+5.4%+3.0%
Q3 2021-0.5%-2.5%-0.2%
Q2 2021+4.1%+3.9%+14.9%
Q1 2021+6.3%+5.6%+3.3%
Q4 2020+7.0%+3.3%-6.1%
Q3 2020+2.7%+5.8%-0.3%
Q2 2020-0.2%+1.7%+6.2%
Q1 2020-0.6%-1.7%+5.3%
Q4 2019-2.6%-1.5%-12.5%
Q3 2019-1.9%-0.9%+3.5%
Q2 2019+1.4%+2.0%+0.5%
Q1 2019+1.6%+2.3%+5.0%
Q4 2018+2.8%+2.8%+18.9%
Q3 2018-4.4%-7.2%-1.7%
Q2 2018+2.5%+4.8%+2.0%
Q1 2018-1.0%-2.2%-1.1%
Q4 2017-2.3%-1.6%-5.8%
Q3 2017+5.5%+5.7%+8.4%
Q2 2017-3.2%-4.4%-5.7%
Q1 2017-5.5%-3.6%-5.0%
Q4 2016+4.0%+3.4%+7.8%
Q3 2016+3.9%+2.1%+2.4%
Q2 2016-0.2%+0.2%-0.8%
Q1 2016+1.6%
Q4 2015-0.2%
Q3 2015+4.2%
Q2 2015-0.1%
Q1 2015-2.3%
Q4 2014-1.0%
Q3 2014+3.9%
Q2 2014-4.3%
Q1 2014-0.2%
Q4 2013+1.4%
Q3 2013+4.1%
Q2 2013+0.4%
Q1 2013-1.1%
Q4 2012-1.2%
Q3 2012-4.9%
Q2 2012-1.9%
Q1 2012-2.8%
Q4 2011-0.6%
Q3 2011+6.4%
Q2 2011-3.1%
Q1 2011-2.1%
Q4 2010+1.8%
Q4 2007+1.8%
Q3 2010+3.8%
Q2 2010-4.4%
Q1 2009+4.8%
Q1 2010+0.4%
Q4 2009-0.1%
Q3 2009-0.8%
Q3 2008-0.8%
Q2 2009-2.4%
Q2 2008-2.4%
Q4 2008-2.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro